Mark Hows

826 total citations
16 papers, 685 citations indexed

About

Mark Hows is a scholar working on Biomedical Engineering, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark Hows has authored 16 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Biomedical Engineering, 5 papers in Molecular Biology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark Hows's work include Microfluidic and Capillary Electrophoresis Applications (6 papers), Innovative Microfluidic and Catalytic Techniques Innovation (4 papers) and Neuroscience and Neuropharmacology Research (4 papers). Mark Hows is often cited by papers focused on Microfluidic and Capillary Electrophoresis Applications (6 papers), Innovative Microfluidic and Catalytic Techniques Innovation (4 papers) and Neuroscience and Neuropharmacology Research (4 papers). Mark Hows collaborates with scholars based in United Kingdom, Italy and Slovakia. Mark Hows's co-authors include Ajit J. Shah, Christian Heidbreder, Laurent Lacroix, Andrew J. Organ, David I. Perrett, Jack F. Kay, Jim J. Hagan, Laurence J. King, Christine J. Darby and N. G. Coldham and has published in prestigious journals such as Journal of Chromatography A, British Journal of Pharmacology and Neuropsychopharmacology.

In The Last Decade

Mark Hows

16 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Hows United Kingdom 10 233 207 120 87 86 16 685
W. Kochen Germany 14 208 0.9× 107 0.5× 71 0.6× 77 0.9× 92 1.1× 37 928
T.R.A. Macedo Portugal 15 236 1.0× 247 1.2× 175 1.5× 51 0.6× 52 0.6× 32 875
Ian N. Acworth United States 17 278 1.2× 168 0.8× 64 0.5× 141 1.6× 83 1.0× 31 929
Valérie Sauvinet France 17 313 1.3× 206 1.0× 41 0.3× 78 0.9× 158 1.8× 31 1.1k
Shimako Yoshitake Sweden 11 178 0.8× 335 1.6× 74 0.6× 26 0.3× 18 0.2× 16 758
Cátia F. Lourenço Portugal 23 314 1.3× 305 1.5× 135 1.1× 14 0.2× 52 0.6× 39 1.0k
Mark Lada United States 9 127 0.5× 141 0.7× 66 0.6× 84 1.0× 261 3.0× 12 566
Päivi Uutela Finland 8 227 1.0× 99 0.5× 80 0.7× 126 1.4× 45 0.5× 13 490
Annika Mälkiä Spain 12 297 1.3× 229 1.1× 47 0.4× 45 0.5× 32 0.4× 14 831
Kevin F. McKenna Canada 12 111 0.5× 139 0.7× 108 0.9× 53 0.6× 20 0.2× 18 504

Countries citing papers authored by Mark Hows

Since Specialization
Citations

This map shows the geographic impact of Mark Hows's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hows with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hows more than expected).

Fields of papers citing papers by Mark Hows

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Hows. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hows. The network helps show where Mark Hows may publish in the future.

Co-authorship network of co-authors of Mark Hows

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Hows. A scholar is included among the top collaborators of Mark Hows based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Hows. Mark Hows is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ito, Kazuhiro, Yasuo Kizawa, Genki Kimura, et al.. (2021). Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in Aspergillus fumigatus infected mice. European Journal of Pharmaceutical Sciences. 163. 105878–105878. 5 indexed citations
2.
Coates, Matthew, Samuel Constant, Song Huang, et al.. (2018). Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. British Journal of Pharmacology. 175(12). 2520–2534. 28 indexed citations
3.
Bianchi, Massimiliano, Ajit J. Shah, K.C.F. Fone, et al.. (2009). Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse. 63(4). 359–364. 45 indexed citations
4.
Quinn, Leann P., Barry Crook, Mark Hows, et al.. (2008). The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. British Journal of Pharmacology. 154(1). 226–233. 100 indexed citations
5.
Hows, Mark, Laurent Lacroix, Christian Heidbreder, Andrew J. Organ, & Ajit J. Shah. (2004). High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samples. Journal of Neuroscience Methods. 138(1-2). 123–132. 165 indexed citations
6.
Hows, Mark, Andrew Billinton, M.J. Perren, et al.. (2004). High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. Journal of Neuroscience Methods. 137(2). 221–226. 17 indexed citations
7.
Lacroix, Laurent, Mark Hows, Abdul Jabbar Shah, J.J. Hagan, & Christian Heidbreder. (2003). The selective dopamine D3 receptor antagonist SB-277011 enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. European Neuropsychopharmacology. 13. S21–S22. 1 indexed citations
8.
9.
Lacroix, Laurent, Mark Hows, Ajit J. Shah, Jim J. Hagan, & Christian Heidbreder. (2002). Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex. Neuropsychopharmacology. 28(5). 839–849. 81 indexed citations
10.
Hows, Mark, Andrew J. Organ, Sarah R. Murray, et al.. (2002). High-performance liquid chromatography/tandem mass spectrometry assay for the rapid high sensitivity measurement of basal acetylcholine from microdialysates. Journal of Neuroscience Methods. 121(1). 33–39. 56 indexed citations
11.
Hows, Mark, et al.. (1998). Optimised Micellar Electrokinetic Capillary Chromatography of UV-Absorbing Compounds in Urine. Advances in experimental medicine and biology. 431. 171–176. 3 indexed citations
12.
Hows, Mark & David I. Perrett. (1998). Effects of buffer depletion in capillary electrophoresis: Development of a continuous flow cathode. Chromatographia. 48(5-6). 355–359. 3 indexed citations
14.
Hows, Mark, David I. Perrett, & Jack F. Kay. (1997). Optimisation of a simultaneous separation of sulphonamides, dihydrofolate reductase inhibitors and β-lactam antibiotics by capillary electrophoresis. Journal of Chromatography A. 768(1). 97–104. 65 indexed citations
15.
Perrett, David I., et al.. (1997). Capillary electrophoresis for small molecules and metabolites. Biochemical Society Transactions. 25(1). 273–278. 5 indexed citations
16.
Hows, Mark & David I. Perrett. (1996). A technique for capillary joining in capillary electrophoresis. Chromatographia. 43(3-4). 200–204. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026